1.Vitamin D Receptor Gene TaqI, BsmI and FokI Polymorphisms in Korean Patients with Tuberculosis.
Tae Jin KANG ; Song Hou JIN ; Chung Eun YEUM ; Seong Beom LEE ; Chi Hong KIM ; Sang Haak LEE ; Kwan Hyoung KIM ; Eun Soon SHIN ; Gue Tae CHAE
Immune Network 2011;11(5):253-257
BACKGROUND: The active metabolite (1, 25-dihydroxycholecalciferol) of vitamin D (25-hydroxycholecalciferol) leads to activation of macrophages and deficiency of vitamin D seems to be involved in the risk of tuberculosis. The effects of vitamin D are exerted by interaction with the vitamin D receptor (VDR) and may be influenced by polymorphism in the VDR gene. In this study, variation in the VDR gene was investigated in Korean population with tuberculosis. METHODS: We typed three VDR polymorphisms of restriction endonuclease sites for TaqI, BsmI and FokI in 155 patients with tuberculosis and 105 healthy volunteers. RESULTS: The frequencies of FokI genotypes determined from TB patients were 29.13% for FF, 56.31% for Ff, and 14.56% for ff. We observed 1.4-fold increased prevalence of the Ff genotype in TB patients compared with normal healthy groups (p=0.0857). However, there was no significant association between the genotype groups, TB patient and normal control, for FokI polymorphism. There was also no significant association between VDR gene and tuberculosis in another polymorphism (BsmI and TaqI). CONCLUSION: Three polymorphisms (TaqI, BsmI and FokI) in the VDR gene do not appear to be responsible for host susceptibility to human tuberculosis in Korean population.
DNA Restriction Enzymes
;
Genotype
;
Humans
;
Macrophages
;
Prevalence
;
Receptors, Calcitriol
;
Tuberculosis
;
Vitamin D
;
Vitamins
2.Vitamin D Receptor Gene TaqI, BsmI and FokI Polymorphisms in Korean Patients with Tuberculosis.
Tae Jin KANG ; Song Hou JIN ; Chung Eun YEUM ; Seong Beom LEE ; Chi Hong KIM ; Sang Haak LEE ; Kwan Hyoung KIM ; Eun Soon SHIN ; Gue Tae CHAE
Immune Network 2011;11(5):253-257
BACKGROUND: The active metabolite (1, 25-dihydroxycholecalciferol) of vitamin D (25-hydroxycholecalciferol) leads to activation of macrophages and deficiency of vitamin D seems to be involved in the risk of tuberculosis. The effects of vitamin D are exerted by interaction with the vitamin D receptor (VDR) and may be influenced by polymorphism in the VDR gene. In this study, variation in the VDR gene was investigated in Korean population with tuberculosis. METHODS: We typed three VDR polymorphisms of restriction endonuclease sites for TaqI, BsmI and FokI in 155 patients with tuberculosis and 105 healthy volunteers. RESULTS: The frequencies of FokI genotypes determined from TB patients were 29.13% for FF, 56.31% for Ff, and 14.56% for ff. We observed 1.4-fold increased prevalence of the Ff genotype in TB patients compared with normal healthy groups (p=0.0857). However, there was no significant association between the genotype groups, TB patient and normal control, for FokI polymorphism. There was also no significant association between VDR gene and tuberculosis in another polymorphism (BsmI and TaqI). CONCLUSION: Three polymorphisms (TaqI, BsmI and FokI) in the VDR gene do not appear to be responsible for host susceptibility to human tuberculosis in Korean population.
DNA Restriction Enzymes
;
Genotype
;
Humans
;
Macrophages
;
Prevalence
;
Receptors, Calcitriol
;
Tuberculosis
;
Vitamin D
;
Vitamins
3.Rifampicin Inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-kappaB DNA-binding Activity in RAW 264.7 Cells.
Seong Keun KIM ; Young Mi KIM ; Chung Eun YEUM ; Song Hyo JIN ; Gue Tae CHAE ; Seong Beom LEE
The Korean Journal of Physiology and Pharmacology 2009;13(6):475-482
Rifampicin is a macrocyclic antibiotic which is used extensively for treatment against Mycobacterium tuberculosis and other mycobacterial infections. Recently, a number of studies have focused on the immune-regulatory effects of rifampicin. Therefore, we hypothesized that rifampicin may influence the TLR2 expression in LPS-activated RAW 264.7 cells. In this study, we determined that rifampicin suppresses LPS-induced TLR2 mRNA expression. The down-regulation of TLR2 expression coincided with decreased production of TNF-alpha. Since NF-kappaB is a major transcription factor that regulates genes for TLR2 and TNF-alpha, we examined the effect of rifampicin on the LPS-induced NF-kappaB activation. Rifampicin inhibited NF-kappaB DNA-binding activity in LPS-activated RAW 264.7 cells, while it did not affect IKKalpha/beta activity. However, rifampicin slightly inhibited the nuclear translocation of NF-kappaB p65. In addition, rifampicin increased physical interaction between pregnane X receptor, a receptor for rifampicin, and NF-kappaB p65, suggesting pregnane X receptor interferes with NF-kappaB binding to DNA. Taken together, our results demonstrate that rifampicin inhibits LPS-induced TLR2 expression, at least in part, via the suppression of NF-kappaB DNA-binding activity in RAW 264.7 cells. Thus, the present results suggest that the rifampicin-mediated inhibition of TLR2 via the suppression of NF-kappaB DNA-binding activity may be a novel mechanism of the immune-suppressive effects of rifampicin.
DNA
;
Down-Regulation
;
Mycobacterium tuberculosis
;
NF-kappa B
;
Receptors, Steroid
;
Rifampin
;
RNA, Messenger
;
Toll-Like Receptor 2
;
Toll-Like Receptors
;
Transcription Factors
;
Tumor Necrosis Factor-alpha
4.Comparison of the Efficacy and Safety between Transradial and Transfemoral Percutaneous Coronary Intervention in Patients with Ischemic Heart Disease.
Min Gyu KONG ; Hye Young JU ; Seok Chun YEUM ; Jin Woo CHOO ; Dae Chul SEO ; In Ki MOON ; Jin Nyoung KIM ; Ho Eun JUNG ; Yun Ju CHO ; Byoung Won PARK ; Jin Wook CHUNG ; Duk Won BANG ; Min Su HYON
Soonchunhyang Medical Science 2012;18(2):81-84
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of transradial percutaneous coronary intervention (TRI) compared with transfemoral percutaneous coronary intervention (TFI) in patients with ischemic heart disease. METHODS: We reviewed retrospectively the medical records including imaging data of the patients with ischemic heart disease who underwent TRI or TFI from January 2007 to December 2009 in Soonchunhyang University Seoul Hospital. We compared major adverse cardiac and cerebrovascular events (MACCEs) including death, myocardial infarction, revascularization, stent thrombosis, and cerebrovascular accident during follow-up period. We also compared procedure related vascular complications including hematoma, arteriovenous fistula, pseudoaneurysm, and infection. RESULTS: Total number of patients was 347 (256 patients of TRI and 91 patients of TFI). There were no significant differences in the rate of MACCEs between two groups. There were significantly less procedure-related vascular complications in TRI group (3.1% vs. 11.0%, P=0.010). CONCLUSION: TRI is as effective as TFI with no difference in the rate of MACCEs in patients with ischemic heart disease. TRI is superior to TFI in safety with reduction of vascular complications.
Aneurysm, False
;
Arteriovenous Fistula
;
Coronary Artery Disease
;
Femoral Artery
;
Follow-Up Studies
;
Heart
;
Hematoma
;
Humans
;
Medical Records
;
Myocardial Infarction
;
Myocardial Ischemia
;
Percutaneous Coronary Intervention
;
Radial Artery
;
Retrospective Studies
;
Stents
;
Stroke
;
Thrombosis